FOLD vs. EXAS, EXEL, RGEN, HALO, MDGL, IONS, ALKS, LGND, GERN, and DVAX
Should you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Geron (GERN), and Dynavax Technologies (DVAX). These companies are all part of the "biotechnology" industry.
Amicus Therapeutics vs.
Amicus Therapeutics (NASDAQ:FOLD) and Exact Sciences (NASDAQ:EXAS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, community ranking, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.
Exact Sciences has a net margin of -7.95% compared to Amicus Therapeutics' net margin of -21.21%. Exact Sciences' return on equity of -6.17% beat Amicus Therapeutics' return on equity.
In the previous week, Exact Sciences had 3 more articles in the media than Amicus Therapeutics. MarketBeat recorded 6 mentions for Exact Sciences and 3 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.16 beat Exact Sciences' score of 0.41 indicating that Amicus Therapeutics is being referred to more favorably in the media.
Amicus Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.
Amicus Therapeutics has higher earnings, but lower revenue than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Amicus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Amicus Therapeutics currently has a consensus target price of $16.88, suggesting a potential upside of 76.15%. Exact Sciences has a consensus target price of $72.76, suggesting a potential upside of 29.82%. Given Amicus Therapeutics' higher probable upside, equities analysts plainly believe Amicus Therapeutics is more favorable than Exact Sciences.
Exact Sciences received 452 more outperform votes than Amicus Therapeutics when rated by MarketBeat users. However, 73.10% of users gave Amicus Therapeutics an outperform vote while only 73.07% of users gave Exact Sciences an outperform vote.
88.8% of Exact Sciences shares are held by institutional investors. 2.2% of Amicus Therapeutics shares are held by company insiders. Comparatively, 1.4% of Exact Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Exact Sciences beats Amicus Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Amicus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amicus Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FOLD) was last updated on 2/1/2025 by MarketBeat.com Staff
